Review Article | Published:

Cardiac contractility modulation therapy in advanced systolic heart failure

Nature Reviews Cardiology volume 10, pages 584598 (2013) | Download Citation

  • A Correction to this article was published on 04 February 2014

This article has been updated

Abstract

Cardiac contractility modulation (CCM) is the application of nonexcitatory electrical signals to the myocardium, during the absolute refractory period of the action potential, to elicit a positive inotropic effect without increasing myocardial oxygen consumption. These effects are independent of QRS duration; consequently, CCM device therapy might benefit symptomatic patients with reduced left ventricular ejection fraction who are not candidates for cardiac resynchronization therapy. Preclinical studies have demonstrated a rapid positive inotropic effect of CCM, which seems to be mediated by modulation of cardiomyocyte Ca2+ fluxes and alterations in the phosphorylation of cardiac phospholamban. In vivo translational and clinical studies that utilized double biphasic voltage pulses to the right ventricular aspect of the interventricular septum have demonstrated positive global effects on cardiac reverse remodelling and contractility. Long-term application of CCM seems to improve patients' exercise tolerance and quality of life. These benefits are apparently accomplished with an acceptable safety profile; however, to date, no data have demonstrated reductions in hospitalizations for heart failure or mortality. CCM is currently available in Europe and ongoing studies are attempting to identify the ideal target population and accumulate additional outcome data.

Key points

  • Cardiac contractility modulation (CCM) is the application of nonexcitatory electrical signals to the myocardium, during the absolute refractory period of the action potential, to augment contraction without increasing oxygen consumption

  • Preclinical studies evolved from using high-amplitude monophasic current pulses to using double-biphasic voltage pulses; the latter have been used in all clinical trials

  • The mechanisms underpinning the effects of CCM are still unclear but might be partly mediated by alterations in myocyte Ca2+ transients and cardiac phospholamban phosphorylation

  • In patients with NYHA class III–IV heart failure, CCM improves reverse remodelling and contractility, independent of QRS duration; these benefits are additive to those of cardiac resynchronization therapy (CRT)

  • CCM improves peak oxygen consumption and quality of life, and these benefits are of a comparable magnitude to those achieved using cardiac resynchronization therapy in patients with prolonged QRS duration

  • Ongoing studies of CCM are generating clinical outcome data and aim to identify the ideal target population for this therapy

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 04 February 2014

    In the version of this article originally published, the address for Alexander R. Lyon was incorrectly stated. The address should have been: NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK. This error has been corrected in the HTML and PDF versions of the article.

References

  1. 1.

    et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875–885 (2010).

  2. 2.

    , & Inotropic effects of electric currents. Circ. Res. 24, 409–445 (1969).

  3. 3.

    et al. Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation 119, 1220–1230 (2009).

  4. 4.

    et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N. Engl. J. Med. 355, 1873–1884 (2006).

  5. 5.

    et al. Reversal of cardiac dysfunction after long-yerm expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112–1119 (2008).

  6. 6.

    et al. Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy. Circulation 109, 2263–2265 (2004).

  7. 7.

    et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. 138, 78–86 (1999).

  8. 8.

    et al. Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 325, 1468–1475 (1991).

  9. 9.

    et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca2+-ATPase in a rat model of heart failure. Circulation 104, 1424–1429 (2001).

  10. 10.

    et al. Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others. Cardiovasc. Toxicol. 5, 355–364 (2005).

  11. 11.

    et al. Electric currents applied during refractory period enhance contractility and systolic calcium in the ferret heart. Am. J. Physiol. Heart Circ. Physiol. 284, H1119–H1123 (2003).

  12. 12.

    , , , & Cardiac contractility modulation by non-excitatory currents: Studies in isolated cardiac muscle. Eur. J. Heart Fail. 8, 7–15 (2006).

  13. 13.

    , & The acute inotropic effects of cardiac contractility modulation (CCM) are associated with action potential duration shortening and mediated by β-adrenoceptor signalling. J. Mol. Cell. Cardiol. 51, 252–262 (2011).

  14. 14.

    & Local control in cardiac E-C coupling. J. Mol. Cell. Cardiol. 52, 298–303 (2012).

  15. 15.

    Calcium cycling proteins and heart failure: mechanisms and therapeutics. J. Clin. Invest. 123, 46–52 (2013).

  16. 16.

    , , & Calcium flux balance in the heart. J. Mol. Cell. Cardiol. 58, 110–117 (2013).

  17. 17.

    et al. Revisiting the ionic mechanisms of early afterdepolarizations in cardiomyocytes: predominant by Ca waves or Ca currents? Am. J. Physiol. Heart Circ. Physiol. 302, H1636–H1644 (2012).

  18. 18.

    & Arrhythmogenic consequences of intracellular calcium waves. Am. J. Physiol. Heart Circ. Physiol. 297, H997–H1002 (2009).

  19. 19.

    , , & Contractile effects of adenovirally-mediated increases in SERCA2a activity: a comparison between rat and rabbit ventricular myocytes. Mol. Cell. Biochem. 251, 103–109 (2003).

  20. 20.

    , , & CaMKII in the cardiovascular system: sensing redox states. Physiol. Rev. 91, 889–915 (2011).

  21. 21.

    et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477, 601–605 (2011).

  22. 22.

    et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J. Am. Coll. Cardiol. 49, 2120–2128 (2007).

  23. 23.

    et al. Augmentation of left ventricular contractility by cardiac sympathetic neural stimulation. Circulation 121, 1286–1294 (2010).

  24. 24.

    , & What is the role of beta-adrenergic signalling in heart failure? Circ. Res. 93, 896–906 (2003).

  25. 25.

    et al. Cardiac contractility modulation by electric currents applied during the refractory period. Am. J. Physiol. Heart Circ. Physiol. 282, H1642–H1647 (2002).

  26. 26.

    et al. Ca2+-binding proteins in dogs with heart failure: effects of cardiac contractility modulation electrical signals. Clin. Transl. Sci. 2, 211–215 (2009).

  27. 27.

    et al. Cardiac contractility modulation electrical signals normalize activity, expression, and phosphorylation of the Na+–Ca2+ exchanger in heart failure. J. Card. Fail. 15, 48–56 (2009).

  28. 28.

    et al. Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associated with increased myocardial oxygen consumption. J. Card. Fail. 13, 137–142 (2007).

  29. 29.

    et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J. Mol. Cell. Cardiol. 42, 852–861 (2007).

  30. 30.

    et al. Long-term effects of non-excitatory cardiac contractility modulation electric signals on the progression of heart failure in dogs. Eur. J. Heart Fail. 6, 145–150 (2004).

  31. 31.

    et al. Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J. Am. Coll. Cardiol. 51, 1784–1789 (2008).

  32. 32.

    et al. SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur. Heart J. 33, 1067–1075 (2012).

  33. 33.

    et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ. Arrhythm. Electrophysiol. 4, 362–372 (2011).

  34. 34.

    et al. Plasticity of surface structures and β2-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure. Circ. Heart Fail. 5, 357–365 (2012).

  35. 35.

    et al. Stable myocardial-specific AAV6–S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 115, 2506–2515 (2007).

  36. 36.

    et al. Cardiac AAV9–S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci. Transl. Med. 3, 92ra64 (2011).

  37. 37.

    et al. Effects of chronic therapy with cardiac contractility modulation electrical signals on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure. Cardiology 110, 230–237 (2008).

  38. 38.

    et al. Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 90, 1307–1313 (2002).

  39. 39.

    et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 102, 3053–3059 (2000).

  40. 40.

    , , , & Alteration of left ventricular performance by left bundle branch block simulated with atrioventricular sequential pacing. Am. J. Cardiol. 53, 99–104 (1984).

  41. 41.

    et al. Electrical signals applied during the absolute refractory period: an investigational treatment for advanced heart failure in patients with normal QRS duration. J. Am. Coll. Cardiol. 46, 2229–2236 (2005).

  42. 42.

    et al. First human chronic Experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure. J. Cardiovasc. Electrophysiol. 15, 418–427 (2004).

  43. 43.

    et al. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur. Heart J. 25, 650–655 (2004).

  44. 44.

    et al. Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. JACC Cardiovasc. Imaging 2, 1341–1349 (2009).

  45. 45.

    et al. Comparison of left ventricular reverse remodeling induced by cardiac contractility modulation and cardiac resynchronization therapy in heart failure patients with different QRS durations. Int. J. Cardiol. 167, 889–893 (2013).

  46. 46.

    et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm 3, 1140–1147 (2006).

  47. 47.

    et al. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 346, 1845–1853 (2002).

  48. 48.

    et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur. Heart J. 29, 1019–1028 (2008).

  49. 49.

    et al. Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay. N. Engl. J. Med. 344, 873–880 (2001).

  50. 50.

    et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am. Heart J. 161, 329–337 (2011).

  51. 51.

    et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J. Am. Coll. Cardiol. 42, 1454–1459 (2003).

  52. 52.

    et al. The ventilatory anaerobic threshold in heart failure: a multicenter evaluation of reliability. J. Card. Fail. 16, 76–83 (2010).

  53. 53.

    , , & Prediction of severe cardiovascular events by VE/VCO2 slope versus peak VO2 in systolic heart failure: A meta-analysis of the published literature. Am. Heart J. 160, 1004–1014 (2010).

  54. 54.

    Does contractility modulation have a role in the treatment of heart failure? Curr. Heart Fail. Rep. 8, 260–265 (2011).

  55. 55.

    , & Cardiac contractility modulation for heart failure: a meta-analysis of randomized controlled trials. Pacing Clin. Electrophysiol. 35, 1111–1118 (2012).

  56. 56.

    et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539–1549 (2005).

  57. 57.

    , , , & Long-term outcome of cardiac contractility modulation in patients with severe congestive heart failure. Europace 13, 1436–1444 (2011).

  58. 58.

    et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113, 1424–1433 (2006).

  59. 59.

    et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J. Am. Coll. Cardiol. 42, 2109–2116 (2003).

  60. 60.

    et al. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J. Card. Fail. 17, 710–717 (2011).

  61. 61.

    US National Library of Medicine. ClinicalTrials.gov , (2012).

  62. 62.

    et al. Altered connexin expression in human congestive heart failure. J. Mol. Cell. Cardiol. 33, 359–371 (2001).

  63. 63.

    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327, 685–691 (1992).

  64. 64.

    , , , & First use of cardiac contractility modulation (CCM) in a patient failing CRT therapy: Clinical and technical aspects of combined therapies. Eur. J. Heart Fail. 9, 955–958 (2007).

  65. 65.

    , & Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. Europace 10, 1375–1380 (2008).

  66. 66.

    et al. Baseline left ventricular dP/dtmax rather than the acute improvement in dP/dtmax predicts clinical outcome in patients with cardiac resynchronization therapy. Eur. J. Heart Fail. 13, 1126–1132 (2011).

  67. 67.

    et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 112, 1580–1586 (2005).

  68. 68.

    et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: The HF-ACTION randomized trial. JAMA 308, 465–474 (2012).

  69. 69.

    et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436–2448 (2009).

  70. 70.

    et al. High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi–dependent manner/clinical perspective. Circulation 126, 697–706 (2012).

Download references

Author information

Affiliations

  1. NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK

    • Alexander R. Lyon
  2.  Minneapolis Heart Institute, Abbott Northwestern Hospital, Suite 300, 920 East 28th Street, Minneapolis, MN 55407, USA

    • Michael A. Samara
    •  & David S. Feldman
  3.  Georgia Insitute of Technology, North Avenue, Atlanta, GA 30332, USA and Morehouse School of Medicine, 720 West Drive, Atlanta, GA 30310, USA

    • David S. Feldman

Authors

  1. Search for Alexander R. Lyon in:

  2. Search for Michael A. Samara in:

  3. Search for David S. Feldman in:

Contributions

The authors contributed equally to researching data for the article, and made substantial contributions to discussion of the content, writing, review, and editing of the manuscript before submission.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to David S. Feldman.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrcardio.2013.114

Further reading